Summary

Borderline personality disorder (BPD) affects approximately 2% of adults, and 11% of patients seeking psychiatric treatment. Previous reports suggested that olanzapine (OLZ) may be useful in the treatment of this disorder. This article presents the results of the double-blind phase of a clinical trial of OLZ in patients with BPD.